Free Submission Public Relations &
Deutsch English


Recent Study: PharmaPoint: Prostate Cancer - United States Drug Forecast and Market Analysis to 2022

Print article Print article
2013-03-03 11:00:51 - Fast Market Research recommends "PharmaPoint: Prostate Cancer - United States Drug Forecast and Market Analysis to 2022" from GlobalData, now available

GlobalData has released its new Country report, "PharmaPoint: Prostate Cancer - United States Drug Forecast and Market Analysis to 2022". The recent approvals of second-line metastatic castration-resistant prostate cancer (mCRPC) therapies like J&J's Zytiga (abiraterone acetate) and Medivation/Astellas' Xtandi (enzalutamide) will drive strong market growth over the next decade. These safe and orally administered treatments will provide safety and convenience benefits over the current standard of care, chemotherapy with docetaxel, while prolonging the overall survival of patients with mCRPC. The December 12, 2012 FDA approval of Zytiga for the added indication of chemotherapy-naive mCRPC marks the onset of a new treatment paradigm for the disease, in which chemotherapy is relegated to second-line therapy and beyond. For patients with earlier-stage prostate

cancer, androgen deprivation therapy with LHRH agonists and first-generation antiandrogens remains the standard of care for suppressing testosterone levels and temporarily controlling the disease.

Full Report Details at
- ..

US prescribers widely use routine PSA screening to diagnose prostate cancer, as well as a DRE. GlobalData's primary research shows that the majority of patients treated by urologists and medical oncologists in the US in 2011 were diagnosed or monitored using PSA screening. The diagnosis is confirmed and the cancer is staged following a TRUS-guided multiple-core needle biopsy, and any metastases are diagnosed using a bone scan or Computed Tomography (CT) scan (NCCN, 2012). Most prescribers surveyed intend to decrease their use of routine PSA screening to diagnose prostate cancer in asymptomatic patients in response to the recent USPSTF recommendation against it (see Section 5.2.2). While GlobalData predicts that the use of routine PSA screening will slightly decrease, we still believe that it will be the primary tool used in the diagnosis of prostate cancer over the forecast period, as there are currently no better, cost-effective options available.


* Overview of RA, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
* Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
* Sales forecast for the top drugs in the US from 2012 to 2022.
* Analysis of the impact of key events as well the drivers and restraints affecting the US Prostate cancer market.

Reasons to buy

* Understand and capitalize by identifying products that are most likely to ensure a robust return
* Stay ahead of the competition by understanding the changing competitive landscape for Prostate cancer
* Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
* Make more informed business decisions from insightful and in-depth analysis of Prostate cancer drug performance in the US
* Obtain sales forecast from 2012-2022 in The US

Partial Table of Contents:

1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.1.3 Prognosis
3.1.4 Quality of Life
3.2 Symptoms
4 Disease Management
4.1 Diagnosis and Referral Overview
4.2 Treatment Overview
4.2.1 Conservative Management Strategies
4.2.2 Localized Treatments
4.2.3 Hormone Therapy
4.2.4 Drug Therapies
4.3 US
4.3.1 Diagnosis
4.3.2 Clinical Practice
5 Competitive Assessment
5.1 Overview
5.2 Strategic Competitor Assessment
5.3 Product Profiles - Major Brands, Hormone Therapies
5.3.1 Zoladex (goserelin acetate)
5.3.2 Lupron Depot (leuprolide acetate)
5.3.3 Eligard (leuprolide acetate)
5.3.4 Trelstar (triptorelin acetate)
5.3.5 Firmagon (degarelix)
5.3.6 Casodex (bicalutamide)
5.4 Product Profiles - Major Brands, Chemotherapies
5.4.1 Taxotere (docetaxel)
5.4.2 Jevtana (cabazitaxel)
5.5 Product Profiles - Major Brands, Therapeutic Vaccines
5.5.1 Provenge (sipuleucil-T)
5.6 Product Profiles - Major Brands, Targeted Therapies
5.6.1 Zytiga (abiraterone acetate)
5.6.2 Xtandi (enzalutamide)
5.7 Product Profiles - Major Brands, Bone Therapies
5.7.1 Xgeva (denosumab)
5.7.2 Zometa (zoledronic acid)
5.8 Other Marketed Hormone and Drug Therapies
6 Opportunity and Unmet Need
6.1 Overview
6.2 Efficacy at Prolonging Overall Survival
6.3 Safety
6.4 Mitigation of Symptoms
6.5 Cost
6.6 Convenient Routes of Administration
6.7 Accurate Diagnostic Tests and Surveillance Tools
6.8 Unmet Needs Gap Analysis
6.9 Opportunity: Targeting Early-Stage, Hormone-Sensitive Prostate Cancer
7 Pipeline Assessment
7.1 Overview
7.2 Promising Drugs in Clinical Development
7.2.1 Cabozantinib
7.2.2 Custirsen Sodium
7.2.3 Sprycel (dasatinib)
7.2.4 Yervoy (ipilimumab)
7.2.5 Orteronel
7.2.6 Alpharadin (radium-223 chloride)
7.2.7 Tasquinimod
7.2.8 ProstVac (Vaccinia-PSA-TRICOM/Fowlpox-PSA-TRICOM)
8 Market Outlook
8.1 United States
8.1.1 Forecast
8.1.2 Key Events
8.1.3 Drivers and Barriers
9 Appendix
9.1 Bibliography
9.2 Abbreviations

Full Table of Contents is available at:

About GlobalData

GlobalData is a leading provider of global business intelligence including market, competitor, product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team. View more research from GlobalData at

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

Bill Thompson
Phone: 18008448156

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News


Terms & Conditions | Privacy | About us | Contact